- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05565378
Fase 2-plattformstudie av nye immunterapikombinasjoner hos deltakere med tidligere ubehandlet, avansert/metastatisk ikke-småcellet lungekreft
En fase 2, randomisert, åpen plattformstudie som bruker en masterprotokoll for å evaluere nye immunterapikombinasjoner hos deltakere med tidligere ubehandlet, lokalt avansert/metastatisk, programmert dødsligand 1-selektert ikke-småcellet lungekreft
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Cipoletti Rio Negro, Argentina, R8324CVE
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
- GSK Investigational Site
-
Florida, Argentina, 1602
- GSK Investigational Site
-
Mar del Plata, Argentina, 7600
- GSK Investigational Site
-
San Juan, Argentina, J5402DIL
- GSK Investigational Site
-
Santa Fe, Argentina, 3000
- GSK Investigational Site
-
-
-
-
-
Wilrijk, Belgia, 2650
- GSK Investigational Site
-
-
-
-
-
Barretos, Brasil, 14784-400
- GSK Investigational Site
-
Porto Alegre, Brasil, 90610-000
- GSK Investigational Site
-
São Paulo, Brasil, 01246-000
- GSK Investigational Site
-
Vitória, Brasil, 29043-260
- GSK Investigational Site
-
-
-
-
-
Abu Dhabi, De forente arabiske emirater
- GSK Investigational Site
-
Abu Dhabi, De forente arabiske emirater, 51900
- GSK Investigational Site
-
-
-
-
-
Oulu, Finland, 90220
- GSK Investigational Site
-
Tampere, Finland, 33520
- GSK Investigational Site
-
Turku, Finland, 20520
- GSK Investigational Site
-
Vaasa, Finland, 65130
- GSK Investigational Site
-
-
-
-
Florida
-
Plantation, Florida, Forente stater, 33322-5426
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87131
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37404
- GSK Investigational Site
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- GSK Investigational Site
-
-
-
-
-
Bordeaux, Frankrike, 33076
- GSK Investigational Site
-
Caen, Frankrike, 14033
- GSK Investigational Site
-
Marseille, Frankrike, 13009
- GSK Investigational Site
-
Quimper, Frankrike, 29107
- GSK Investigational Site
-
Strasbourg, Frankrike, 67091
- GSK Investigational Site
-
-
-
-
-
Athens, Hellas, 11528
- GSK Investigational Site
-
Pylaia Thessaloniki, Hellas, 57001
- GSK Investigational Site
-
Thessaloniki, Hellas, 54645
- GSK Investigational Site
-
-
Attica
-
Athens, Attica, Hellas, 115 27
- GSK Investigational Site
-
Chaïdári, Attica, Hellas, 124 62
- GSK Investigational Site
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Hellas, 570 10
- GSK Investigational Site
-
-
Thessaly
-
Larissa, Thessaly, Hellas, 411 10
- GSK Investigational Site
-
-
-
-
-
Avellino, Italia, 83100
- GSK Investigational Site
-
Bergamo, Italia, 24125
- GSK Investigational Site
-
Pisa, Italia, 57124
- GSK Investigational Site
-
Verona, Italia, 37045
- GSK Investigational Site
-
-
GE
-
Genova, GE, Italia, 16132
- GSK Investigational Site
-
-
-
-
-
Chiba, Japan, 277-8577
- GSK Investigational Site
-
Fukuoka, Japan, 812-8582
- GSK Investigational Site
-
Hyōgo, Japan, 673-8558
- GSK Investigational Site
-
Kanagawa, Japan, 241-8515
- GSK Investigational Site
-
Osaka, Japan, 590-0197
- GSK Investigational Site
-
Saitama, Japan, 350-1298
- GSK Investigational Site
-
-
-
-
-
Guadajalara, Mexico, 44280
- GSK Investigational Site
-
San Luis Potosí City, Mexico, 78209
- GSK Investigational Site
-
-
-
-
-
Enschede, Nederland, 7512 KZ
- GSK Investigational Site
-
Groningen, Nederland, 9728 NZ
- GSK Investigational Site
-
Leeuwarden, Nederland, 8934 AD
- GSK Investigational Site
-
Utrecht, Nederland, 3543 AZ
- GSK Investigational Site
-
-
-
-
-
Lublin, Polen, 20-954
- GSK Investigational Site
-
Prabuty, Polen, 82-550
- GSK Investigational Site
-
Siedlce, Polen, 08-110
- GSK Investigational Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- GSK Investigational Site
-
Lisbon, Portugal, 1500-650
- GSK Investigational Site
-
Lisbon, Portugal, 1998-018
- GSK Investigational Site
-
Porto, Portugal, 4200-072
- GSK Investigational Site
-
Vila Nova de Gaia, Portugal, 4434-502
- GSK Investigational Site
-
-
-
-
-
Badajoz, Spania, 06080
- GSK Investigational Site
-
Barcelona, Spania, 08035
- GSK Investigational Site
-
Las Palmas de Gran Canar, Spania, 35016
- GSK Investigational Site
-
Madrid, Spania, 28041
- GSK Investigational Site
-
Madrid, Spania, 28046
- GSK Investigational Site
-
Madrid, Spania, 28027
- GSK Investigational Site
-
Málaga, Spania, 29010
- GSK Investigational Site
-
PamplonaNavarra, Spania, 28027
- GSK Investigational Site
-
Valencia, Spania, 46026
- GSK Investigational Site
-
Valencia, Spania, 46009
- GSK Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spania, 08916
- GSK Investigational Site
-
L'Hospitalet de Llobregat, Barcelona, Spania, 08907
- GSK Investigational Site
-
-
-
-
-
Middlesbrough, Storbritannia, TS4 3BW
- GSK Investigational Site
-
Wolverhampton, Storbritannia, WV10 0QP
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Storbritannia, HA6 2RN
- GSK Investigational Site
-
-
-
-
-
Incheon, Sør -Korea, 21565
- GSK Investigational Site
-
Seoul, Sør -Korea, 03080
- GSK Investigational Site
-
Seoul, Sør -Korea, 03722
- GSK Investigational Site
-
Suwon Gyeonggi-do, Sør -Korea, 442-723
- GSK Investigational Site
-
-
-
-
-
Cape Town, Sør-Afrika, 7570
- GSK Investigational Site
-
Parktown, Sør-Afrika, 2193
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10210
- GSK Investigational Site
-
Chiang Mai, Thailand, 50200
- GSK Investigational Site
-
Kho Hong Hat Yai, Thailand, 90110
- GSK Investigational Site
-
Khon Kaen, Thailand, 40002
- GSK Investigational Site
-
Pathum Thani, Thailand, 12120
- GSK Investigational Site
-
-
-
-
-
Ankara, Tyrkia (Türkiye), 06800
- GSK Investigational Site
-
Ankara, Tyrkia (Türkiye), 06680
- GSK Investigational Site
-
Antalya, Tyrkia (Türkiye), 07070
- GSK Investigational Site
-
Istanbul, Tyrkia (Türkiye), 34214
- GSK Investigational Site
-
-
Atakum
-
Samsun, Atakum, Tyrkia (Türkiye), 55200
- GSK Investigational Site
-
-
-
-
-
Berlin, Tyskland, 13125
- GSK Investigational Site
-
Heidelberg, Tyskland, 69126
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Tyskland, 45147
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Tyskland, 22927
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- GSK Investigational Site
-
-
-
-
-
Budapest, Ungarn, H-1121
- GSK Investigational Site
-
Gyöngyös, Ungarn, 3200
- GSK Investigational Site
-
Tatabánya, Ungarn, 2800
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
- No prior systemic therapy for their locally advanced or metastatic NSCLC
- Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
- PD-L1-high (TC/TPS >= 50%) tumor
- Measurable disease based on RECIST 1.1, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate Baseline organ function
- Female participants of childbearing potential must use adequate contraception
Exclusion Criteria:
- Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
- Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
- Received prior therapy with any immune checkpoint inhibitors
- Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
- Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
- Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
- Received any live vaccine <= 30 days prior to first dose of study intervention
- Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- History or evidence of cardiac abnormalities
- Current unstable liver or biliary disease
- Severe infection within 4 weeks prior to the first dose of study intervention
- Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
- Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
- Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
- Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Pembrolizumab Monotherapy
Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
Pembrolizumab will be administered. |
|
Eksperimentell: Dostarlimab Monotherapy
Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
Dostarlimab will be administered
Andre navn:
|
|
Eksperimentell: Substudy 1A
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
Belrestotug will be administered.
Andre navn:
Dostarlimab will be administered
Andre navn:
|
|
Eksperimentell: Substudy 1B
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
Belrestotug will be administered.
Andre navn:
Dostarlimab will be administered
Andre navn:
|
|
Eksperimentell: Substudy 1C
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
Belrestotug will be administered.
Andre navn:
Dostarlimab will be administered
Andre navn:
|
|
Eksperimentell: Substudy 2A
Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
Belrestotug will be administered.
Andre navn:
Nelistotug will be administered.
Andre navn:
Dostarlimab will be administered
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antall deltakere med behandling av fremvoksende bivirkninger (TEAE) og alvorlige bivirkninger (SAE)
Tidsramme: Opptil 228 uker
|
Opptil 228 uker
|
|
Antall deltakere med Teaes eller SAE -er som fører til dosemodifikasjoner eller behandlingsoppsamling
Tidsramme: Opptil 228 uker
|
Opptil 228 uker
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 213824
- 2021-005115-32 (EudraCT-nummer)
- GALAXIES LUNG-201 (Annen identifikator: Study Identifier)
- 2023 (U.S. NIH-stipend/kontrakt)
- 2023-505057-40-00 (Registeridentifikator: CTIS (EU))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Tilgangskriterier for IPD-deling
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .